Y-mAbs Therapeutics, Inc. (YMAB)
| Market Cap | 509.75M |
| Revenue (ttm) | 40.00M |
| Net Income (ttm) | -116.76M |
| Shares Out | 43.72M |
| EPS (ttm) | -2.68 |
| PE Ratio | n/a |
| Forward PE | 119.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 369,063 |
| Open | 11.14 |
| Previous Close | 10.98 |
| Day's Range | 10.62 - 11.67 |
| 52-Week Range | 6.50 - 39.82 |
| Beta | 1.47 |
| Analysts | Buy |
| Price Target | 30.43 (+161.0%) |
| Earnings Date | May 9, 2022 |
About YMAB
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neurob...
Financial Performance
In 2021, YMAB's revenue was $34.90 million, an increase of 68.18% compared to the previous year's $20.75 million. Losses were -$55.28 million, -53.68% less than in 2020.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for YMAB stock is "Buy." The 12-month stock price forecast is 30.43, which is an increase of 160.98% from the latest price.
News
Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary Endpoint
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializa...
YmAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Lags Revenue Estimates
YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 9.86% and 0.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments
NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializat...
Y-mAbs to Announce First Quarter 2022 Financial and Operating Results on May 9, 2022
NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter March 31, 2022 o...
Earnings Preview: YmAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline
YmAbs Therapeutics, Inc. (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Y-mAbs Announces Executive Management Changes and Provides 2022 Revenue Guidance and Financial Update
NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializ...
Y-mAbs Announces Presentation of SADA Technology at AACR
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializ...
Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA
NEW YORK, April 01, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializ...
YmAbs Therapeutics, Inc. (YMAB) Soars 11.3%: Is Further Upside Left in the Stock?
YmAbs Therapeutics, Inc. (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri...
Moore Kuehn, PLLC Encourages Investors of Y-mAbs Therapeutics, Inc. to Contact Law Firm
New York, New York--(Newsfile Corp. - March 17, 2022) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Y-mAbs Therapeutics, I...
YmAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Misses Revenue Estimates
YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -19.72% and 7.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Y-mAbs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Developments
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializa...
Earnings Preview: YmAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline
YmAbs Therapeutics, Inc. (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Y-mAbs (YMAB) Stock Up on Pre-BLA Meeting Completion With FDA
Following a pre-BLA meeting with the FDA, Y-mAbs Therapeutics (YMAB) expects to resubmit its filing for omburtamabin CNS/leptomeningeal metastases from neuroblastoma by the end of first-quarter 2022.
Y-mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab
NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializa...
YmAbs Therapeutics, Inc. (YMAB) Soars 8.3%: Is Further Upside Left in the Stock?
YmAbs Therapeutics, Inc. (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri...
UPDATE - Y-mAbs Announces Pipeline Update
NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializa...
Y-mAbs Hosting Virtual Research and Development Day
NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializa...
YmAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Misses Revenue Estimates
YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -10.00% and -15.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the ...
Y-mAbs Announces Third Quarter Financial Results and Recent Corporate Developments
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializa...
Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma CNS/LM Metastasis
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializa...
Y-mAbs to Announce Third 2021 Financial and Operating Results on November 4, 2021
NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended September...
Y-mAbs Announces Data to be Presented at SIOP 2021
NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, a...
Y-mAbs Announces Priority Review of BLA for DANYELZA® (naxitamab-gqgk) in China
NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”), NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commerciali...
Y-mAbs to Host Key Opinion Leader Webinar on DANYELZA® (naxitamab-gqgk) Frontline and HITS Data in High-Risk Neurobla...
NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializ...